RSS Content
| Alcon Commences Phase 2 Clinical Trial of NovaBay's NVC-422 for Viral Conjunctivitis |
NovaBay has a licensing and research collaboration agreement with Developed by NovaBay to mimic the body’s defense against infection, Aganocides® are proprietary synthetic analogs of the same molecules used by white blood cells to destroy harmful microbes in the body, such as viruses and bacteria. Because of their natural mechanism of action, NovaBay believes that Aganocide® compounds have a low potential for generating microbial resistance, offering a potential solution to the problem of rising resistance of microbes to traditional antibiotics. The Phase 2 viral conjunctivitis study follows a recently completed Phase 1 trial in which safety and tolerability were successfully demonstrated in 120 healthy volunteers with no reported serious adverse events.
"We are pleased to be entering mid-stage clinical testing for viral
conjunctivitis,” said
The Phase 2 multi-center, randomized, placebo-controlled trial is
designed to determine the safety and efficacy of NVC-422 in people with
viral conjunctivitis. The study calls for enrolling approximately 250
patients at more than 30 medical centers, mostly in
"This study is an important step forward with the clinical program for
this potentially dual-acting therapy to address the multiple causes of
conjunctivitis. Dual action against viral and bacterial conjunctivitis
is important because when an infection is diagnosed it is difficult,
time-consuming and expensive to determine the underlying cause of the
infection and treat it properly," said Dr. About Conjunctivitis Conjunctivitis, which can result from either viral or bacterial infection, is an inflammation of the thin, clear tissue that covers the white part of the eye and forms the inside lining of the eyelid. The viral disease is principally caused by adenoviruses, but also can be caused by other viruses, such as enterovirus. There is no specific treatment for adenoviral conjunctivitis, which can take up to three weeks or longer to clear on its own. Bacterial conjunctivitis is caused by a variety of bacteria and is largely treated with topically applied antibiotic eye drops. Regular innovation to develop newer antibiotics is required because over time antibiotics may encounter increasing bacterial resistance. About Aganocide® Compounds The Aganocide® compounds are novel, proprietary, synthetic N-chlorinated antimicrobial molecules specifically developed by NovaBay to mimic the body’s natural defense against infection. The Aganocide® compounds maintain the biological activities while improving the stability of naturally occurring N-chlorinated antimicrobial molecules. These highly differentiated compounds may deliver the same or better efficacy than currently used antibiotics without contributing to the growing rise of antibiotic-resistant bacterial strains. In preclinical testing, the Aganocide® compounds have been shown to be highly effective against bacteria, viruses and fungi. They also have been demonstrated to be effective against bacteria in biofilms, which render most antibiotics ineffective. Aganocides have a broad therapeutic index while providing a high degree of potency, good tolerability as well as dosing versatility and flexibility.
About
About NovaBay
Forward-Looking Statements
The statements in this press release regarding NovaBay’s and Alcon’s
expectations regarding the clinical trial and the potential efficacy of
Aganocide® compounds are forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995. The
forward- looking statements reflect the views of the management of
NovaBay and Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6000056&lang=en
Source:
Alcon, Inc. |